Development of an opsonophagocytic killing assay for group a streptococcus
•OPKA developed for a number of clinically relevant Group A Streptococcus.•Homologous M-protein antisera shown to kill GAS emm-types 1, 6 and 12.•Killing inhibited by homologous but not heterologous antigens proving specificity.•GAS OPKA is precise; with intra and inter-assay coefficients of variati...
Gespeichert in:
Veröffentlicht in: | Vaccine 2018-06, Vol.36 (26), p.3756-3763 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •OPKA developed for a number of clinically relevant Group A Streptococcus.•Homologous M-protein antisera shown to kill GAS emm-types 1, 6 and 12.•Killing inhibited by homologous but not heterologous antigens proving specificity.•GAS OPKA is precise; with intra and inter-assay coefficients of variation |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2018.05.056 |